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ORIGINAL ARTICLE PARASITOLOGYAmniocentesis for the detection of congenital toxoplasmosis: results from
the nationwide Austrian prenatal screening programA.-R. Prusa1, D. C. Kasper2, A. Pollak1, M. Olischar1, A. Gleiss3 and M. Hayde1
1) Department of Pediatrics and Adolescent Medicine, 2) Research Core Unit for Pediatric Biochemistry and Analytics and 3) Centre for Medical Statistics,
Informatics and Intelligent Systems, Medical University of Vienna, Vienna, AustriaAbstractPrenatal diagnosis of congenital toxoplasmosis (CT) inﬂuences therapeutical management in pregnant women and their offspring. In Austria, a
nationwide serological healthcare program to identify potential maternal toxoplasma infections during pregnancy exists. We assessed the
clinical use of amniocentesis for toxoplasma-speciﬁc polymerase chain reaction (PCR) on amniotic ﬂuid to detect CT. Data on serology,
amniocentesis, PCR, complications, treatment, and paediatric clinical outcome were collected retrospectively among the birth cohort
1992–2008. There were 1386 women with amniocentesis, but only in 707 cases (51%) was acute maternal infection conﬁrmed
serologically. A high proportion (49%) of amniocenteses with negative PCR results in women with chronic infection or seronegativity
were performed without clinical justiﬁcation for the women or their foetuses. The positive and negative predictive values of PCR were
94.4% and 99.3%, respectively. Thirty-nine foetuses with CT, including four deaths, were reported. The ﬁve PCR-negative but infected
infants were identiﬁed by the serological and clinical follow-up program. Thirty percent of amniocenteses were performed in the third
trimester, and gestational age or treatment did not inﬂuence PCR sensitivity. Amniocentesis is indicated in women with acute maternal
infection, and facilitated targeted therapies in pregnant women and their offspring. In women with late toxoplasma infection, negative
amniotic ﬂuid PCR made treatment of infants unnecessary. Serological and clinical follow-up of infants is important to conﬁrm the
infection status of the infant. Recommendations, based on our 17-year experience, to improve the current diagnostic strategies and to
reduce unnecessary amniocentesis, are given.
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E-mail: david.kasper@meduniwien.ac.atIntroductionThe clinical severity of congenital toxoplasmosis (CT) varies from
no clinical signs to major manifestations with severe central ner-
vous system impairment and death [1]. Even though the symp-
tomatic formofCT is rare, it remains aworldwide health problem.Clinical Microbiology and Infection © 2014 European Society of CIn Austria, a mandatory screening for toxoplasma-speciﬁc
antibodies exists [2]. In this healthcare program, seronegative
women are retested serologically until birth. Acute maternal
infection during pregnancy (AI) might result in materno-foetal
transmission, thus, treatment according to the Austrian guide-
lines is recommended. Several studies have shown the positive
effect of treatment on transmission as well as clinical sequelae
of CT [3–15].
PCR of amniotic ﬂuid is the standard test for diagnosing CT
with high sensitivity [16–19], and can be performed early in
pregnancy (starting from week 15 of gestational age) [20]. The
importance of PCR has already been described in several
studies [17–19,21–27] and is essential for further treatmentClin Microbiol Infect 2015; 21: 191.e1–191.e8
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.09.018
191.e2 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMImanagement of both mother and infant. In Austria, amniocen-
tesis is standard practice since 1992, and is an additional
investigation during pregnancy.
In this study we assessed the clinical practices of amniocentesis
in the context of a mandatory prevention program (Austrian
Toxoplasmosis Screening Program). Hereby, a standard program
covers serological testing during pregnancy and treatment of
women and infected infants. Furthermore, medical care of infants
is part of a standard early-childhood program covered by national
healthcare providers. Additionally, we collected data on sero-
logical testing during pregnancy and treatment of women and
infected infants, as well as information on amniocentesis, com-
plications, and clinical follow-up of infants in a database (Austrian
Toxoplasmosis Register) over a 17-year observational period.
Materials and methodsThis retrospective study included 1386 pregnant women (16
twin pregnancies) with amniocentesis for PCR and their foe-
tuses (n = 1402), 1992–2008 (Fig. 1). In 1362 of these cases,
immunoglobulins (Igs) were detected, including women with AI
and chronic infection. Six women had known immunodeﬁ-
ciencies or inborn errors of metabolisms, and thus were
excluded. In another 24 women, amniocenteses were per-
formed due to pathologies in prenatal ultrasound, and these
women were seronegative. Finally, 707 of 1386 (51%) immu-
nocompetent women with AI and 39 infants with CT were
included for ﬁnal statistical analysis.1386 women w
toxoplasma-specific PCR
Seropositive women
(toxoplasma specific IgG positive)
1362/1386 (98%)
Women with chronic
infection (excluded)*
655/1386 (47%)
FIG. 1. Flow chart of women enrolled in this study (n = 1386). Amniocentese
and in women with pathologies in prenatal ultrasound. The serologic diagnosi
Group. PCR, polymerase chain reaction of amniotic ﬂuid. *Including six wom
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectAustrian prenatal screening programThe mandatory serological screening was standard procedure
for all pregnant women and covered by the national healthcare
providers in Austria [2]. Routine screening was mandated by
the obstetrician within the ﬁrst visit and performed at clinical
laboratories by different automated analysers (IgG, IgM, IgG
avidity test). In women with chronic infection, only one test,
and in seronegative women, bi-monthly testing, was recom-
mended. In case of undetermined serology, unclear infection
status, or AI, conﬁrmatory testing at the Reference Laboratory
using in-house Sabin-Feldman dye test and immunosorbent
agglutination assay (bioMérieux, Marcy L’Etoile, France) were
performed. Moreover, our laboratory offered counselling for
physicians and parents as well as an outpatient clinic for follow-
up of women and infants.
Serological test results were interpreted retrospectively at
the Reference Laboratory in accordance with the criteria of the
European Toxoplasmosis Group [28]. The maternal infection
status was deﬁned as follows:
1. Suspected acute maternal infection: The ﬁrst screening test
was IgG/IgM positive; serological re-testing was requested
to assign infection status.
2. AI: Seroconversions, rising titre, or primary high titre (IgG/
IgM positive, IgG avidity).
3. Chronic infection: Stable high IgG and IgM negative, high IgG
at beginning of pregnancy.ith amniocentesis for
 (including 16 twin pregnancies)
Women with acute maternal
toxoplasma infection
707/1386 (51%)
Seronegative women with pathologies 
in prenatal ultrasound 
(excluded)
24/1386 (2%)
s were performed on Toxoplasma gondii – seropositive pregnant women
s was made in accordance with criteria of the European Toxoplasmosis
en with immunodeﬁciency or inborn errors of metabolism.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 191.e1–191.e8
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status in infants: The reference standard for diagnosing
CT was deﬁned as presence of IgG in serum after 1 year
of age. Infants with negative serology after 1 year were
considered as non-infected.
Additionally, amniocentesis was performed at local prena-
tal care clinics (costs were not covered by healthcare pro-
viders). After amniocenteses, 10–20-mL amniotic ﬂuid
samples were shipped at room temperature for PCR di-
agnostics to the Reference Laboratory, Medical University of
Vienna, Austria. DNA was extracted within 24 hours, and
PCR for Toxoplasma gondii B1 gene was performed as re-
ported previously [29,30].
Treatment of pregnant women and infected infants was part
of the routine care. For AI, treatment was prescribed after
seropositivity until birth [31]. Regimen depended on gestational
age (GA): (a) Before week 16 of GA 2.3 g per day (in three
doses) of spiramycin was prescribed; (b) At week 16 of GA and
thereafter, treatment was initiated with the combination of
pyrimethamine (ﬁrst day 50 mg, further 29 days 25 mg)/sulfa-
diazine (ﬁrst day 1500 mg, further 29 days 750 mg)/folinic acid
(3× per week 15 mg) for 4 weeks. Further prescription was
depending on PCR result. Medication was changed every 4
weeks between combination and spiramycin. Women with
negative PCR were treated with spiramycin only. Infants were
treated immediately after birth for 12 months [32]; regimen
depended on clinical manifestation. In infants without manifes-
tation, oral treatment was initiated with combination of pyri-
methamine (1 mg/kg per day)/sulfadiazine (85 mg/kg per day
divided in four doses)/folinic acid (2× per week 5 mg) for 6
weeks. Afterward, treatment changed to 6 weeks spiramycin
(2× per day 50 mg/kg) and 4 weeks combination. In infants with
manifestation, combination was prescribed for 6 months, and
afterward, treatment changed to 6 weeks spiramycin und 4
weeks combination.
The prevention program included mandatory examinations
for infants in early childhood, and costs were covered by
healthcare providers. In addition, affected infants received
specialized care (ophthalmoscopy, cranial ultrasound, serology,
physical and neurological examination). Medical care of women
and infants was provided by local clinics or physicians in
accordance with the Reference Laboratory. Since 1992, labo-
ratory and clinical information on women and infants, including
treatment, amniocenteses, and PCR results, were recorded in
the Austrian Toxoplasmosis Register. This register was per-
formed in an interdisciplinary cooperation between physicians,
laboratories, midwifes, prenatal care clinics, and parents. Over
the past years, all identiﬁed cases of AI and CT were included in
this register.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InStatistical methodsWeeks of gestation and time interval between considered
events, such as seronegativity and seropositivity, were presented
as median and conﬁdence interval (CI; non-normal distribution).
Seronegativity in women was deﬁned as week of GA at last
negative serology, and seropositivity as week of GA at ﬁrst
positive serology during pregnancy. Length of pregnancy was
stated as postmenstrual age in weeks. The ﬁrst trimester lasted
up to 12 weeks of gestation, the second from 13 to 26 weeks,
and the third from 27 weeks to term. Comparison between
trimesters was performed using Wilcoxon’s rank-sum test. p-
Values were not corrected for multiple testing. Reference
standard to calculate sensitivity and speciﬁcity was serological
diagnosis of CT at 1 year. Sensitivity, speciﬁcity, and positive and
negative predictive values were presented as the 95% CI. Two-
by-two comparisons of categorical variables were compared
using Fisher’s Exact test, e.g. between trimesters. Statistical tests
were conducted using SAS version 9.2 (SAS Institute Inc., NC,
USA); p-values <0.05 were considered to be signiﬁcant.
The ethics committee at the Medical University of Vienna,
Vienna, Austria approved this study (No. 824/2009). All women
gave their informed consent.ResultsThis study comprised 1386 women (Fig. 1) with amniocentesis
for PCR, and included 16 twin pregnancies with punctures of
both amniotic sacs (all negative PCR). In 679/1386 (49%)
women, AI was ruled out retrospectively by analysis of sero-
logic data (24 seronegative women and 655 chronic infections).
In all of these cases, PCR was negative and their infants were
non-infected. In 108/655 (16.5%) women with chronic infec-
tion, serological re-testing was necessary to conﬁrm infection
status. In the remaining 83.5% (547/655), the diagnosis of
chronic infection was clear within the ﬁrst serology. In 51%
(707/1386) of women with conﬁrmed AI, amniocentesis for
PCR was justiﬁed. No conventional complications associated
with amniocentesis, like infections, premature contractions, or
rupture of the membranes, were recorded. Furthermore, in
this group, seven women with repeated amniocenteses were
also reported. In two of these women, positive PCR (two times
and three times) revealed infected infants (time interval be-
tween amniocenteses was 3 weeks). The remaining ﬁve women
with non-infected infants had negative PCR results two times
during pregnancy (time interval was at least 5 weeks).
In 39 infected foetuses of these 707 women (5.5%), CT was
conﬁrmed (details are shown in Table 1). In 35 infected infants,fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 191.e1–191.e8
TABLE 1. Maternal serology, treatment, and amniotic ﬂuid PCR results in infants with congenital toxoplasmosis
#
Maternal
infection
Serology of
the mother
(wks)a
AC
(wks)
Maternal
treatment
(wks)
Type of
maternal
treatment
Maternal
treatment
regimen
after AC
Delivery
(wks)
Serology of
infants at
birthb
Prenatal
ultrasound Diagnosis Outcome
AF PCR positive and congenital toxoplasmosis conﬁrmed by serological tests or histopathological examination
1 SC 11–25 25 25–29 PS Austrian 29 No result Hydrocephalus,
growth
retardation
Prenatal Termination
of pregnancyd
2 SC 8–9 22 11–17 S Other 22 No result Hydrocephalus,
ascites,
hepatomegaly
Prenatal Termination
of pregnancyd
3 SC 10–22 23 No No No 24 1:4096
Negative
Hydrocephalus,
ascites
Prenatal Miscarriaged
4 SC 10–33 33 No No No 34 No result Growth
retardation
Prenatal Miscarriaged
5 SC 10–26 30 28–40 SPS Austrian 40 1:65 536
Positive
Hydrocephalus Prenatal Clinical
manifestation
6 SC 12–29 30 30–42 SPS Austrian 42 1:65 536
Negative
Hydrocephalus,
calciﬁcations
Prenatal Clinical
manifestation
7 SC 12–26 26 27–36 SPS Austrian 36 No result Hydrocephalus Prenatal Clinical
manifestation
8 SC 8–20 21 21–37 SPS Austrian 37 No result Ventricle
asymmetry
Prenatal Clinical
manifestation
9 SC 19–33 33 34–37 SP Austrian 37 IgG positive
Positivec
Ventriculomegaly,
hydronephrosis
Prenatal No speciﬁc signs
10 SC 5–27 30 27–38 SPS Other 38 1:65 536
Negative
Normal Prenatal No speciﬁc signs
11 SC 4–21 23 22–40 SPS Austrian 40 1:65 536
Positive
Normal Prenatal No speciﬁc signs
12 SC <16–27 33 30–40 SPS Austrian 40 1:16 384
Negative
Normal Prenatal No speciﬁc signs
13 SC 5–35 36 35–40 SP Austrian 40 1:65 536
Negative
Normal Prenatal No speciﬁc signs
14 SC 11–25 32 32–40 S Other 40 1:65 536
Negative
Normal Prenatal No speciﬁc signs
15 SC 20–26 28 28–38 SPS Austrian 38 1:4096
Negative
Normal Prenatal No speciﬁc signs
16 SC 6–17 22 17–41 SPS Austrian 41 IgG positive
Positivec
Normal Prenatal No speciﬁc signs
17 SC 8–24 30 30–39 SP Austrian 39 1:65 536
Negative
Normal Prenatal No speciﬁc signs
18 SC 25–36 36 36–41 SP Austrian 41 IgG positive
Negativec
Normal Prenatal No speciﬁc signs
19 SC 9–28 30 30–39 SPS Austrian 39 1:65 536
Positive
Ventriculomegaly,
hydronephrosis
Prenatal No speciﬁc signs
20 SC 14–23 29 29–33 S Other 41 1:65 536
Negative
Normal Prenatal No speciﬁc signs
21 SC 27–37 39 38–39 SP Austrian 39 1:4096
Positive
Normal Prenatal No speciﬁc signs
22 SC 9–27 28 27–39 SPS Austrian 39 1:65 536
Negative
Normal Prenatal No signs
23 SC 14–32 33 34–38 S Other 38 1:65 536
Positive
Normal Prenatal No speciﬁc signs
24 SC 21–35 41 37–41 SP Austrian 41 1:4096
Negative
Normal Prenatal No speciﬁc signs
25 SC 25–35 36 36–38 SP Austrian 38 1:65 536
Positive
Normal Prenatal No speciﬁc signs
26 PHT ?–16 24 20–41 SPS Austrian 41 IgG positive
Negativec
Normal Prenatal No speciﬁc signs
27 SC 10–29 30 31–39 SPS Austrian 39 1:65 536
Positive
Normal Prenatal No speciﬁc signs
28 SC 21–26 30 30–41 SPS Austrian 41 1:16 384
Negative
Normal Prenatal No speciﬁc signs
29 SC 9–22 30 28–35 SP Austrian 35 1:65 536
Negative
Normal Prenatal No speciﬁc signs
30 PHT ?–15 25 25–41 SPS Austrian 41 1:16 384
Negative
Normal Prenatal No speciﬁc signs
31 SC 8–21 22 22–39 SPS Austrian 39 IgG positive
Positivec
Normal Prenatal No speciﬁc signs
32 SC 7–28 30 29–41 SPS Austrian 41 1:65 536
Negative
Normal Prenatal No speciﬁc signs
33 SC 25–36 37 37–41 SP Austrian 41 1:65 536
Negative
Normal Prenatal No speciﬁc signs
34 SC 27–33 34 34–40 S Other 40 No result Normal Prenatal No speciﬁc signs
AF PCR negative and congenital toxoplasmosis conﬁrmed by serological tests
35 PHT ?–14 21 15–36 SPS Other 36 1:65 536
Negative
Normal Speciﬁc clinical
signs at 2 months
Clinical
manifestation
36 SC 7–27 31 30–40 SPS Other 40 1:65 536
Negative
Normal IgM positivity at 3
days
No speciﬁc signs
37 SC 9–28 28 28–41 SPS Austrian 41 1:4096
Negative
Normal IgM positivity and
IgG persistence
at 12 months
No speciﬁc signs
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TABLE 1. Continued
#
Maternal
infection
Serology of
the mother
(wks)a
AC
(wks)
Maternal
treatment
(wks)
Type of
maternal
treatment
Maternal
treatment
regimen
after AC
Delivery
(wks)
Serology of
infants at
birthb
Prenatal
ultrasound Diagnosis Outcome
38 SC <16–26 33 28–33 SP Other 38 No result Normal IgM positivity at
four months
No speciﬁc signs
39 SC 9–18 18 18–38 SP Other 41 1:65 536
Positive
Normal IgM positivity at
the cord blood
No speciﬁc signs
AC, amniocentesis; AF, amniotic ﬂuid; PS, pyrimethamine, sulfadiazine and folinic acid; SPS, spiramycin alternating with pyrimethamine, sulfadiazine, and folinic acid; S, spiramycin; SC,
proven seroconversion during pregnancy; PHT, primary high titre (Sabin-Feldman dye test positive, IgM positive); wks, weeks of gestational age.
aLast negative and ﬁrst positive serologic test result during pregnancy.
bCord blood or peripheral venous blood (Sabin-Feldman dye test and ISAGA-IgM result) at birth.
cOther anti-toxoplasma IgG and IgM assay.
dLesions characteristic of toxoplasmosis by histopathological examination.
CMI Prusa et al. Amniocentesis for the detection of congenital toxoplasmosis 191.e5diagnosis was conﬁrmed serologically at 1 year of age and in the
remaining four foetuses (two miscarriages and two termina-
tions of pregnancy) by histopathology. PCR identiﬁed 34/39
foetuses (87.2%) with conﬁrmed CT accurately (including those
two cases of miscarriages and two terminations). In two cases
with positive PCR, the follow-up of the infant excluded CT.
Details of PCR results are provided in Table 2. PCR showed an
overall sensitivity of 87.2%, speciﬁcity of 99.7%, positive pre-
dictive value of 94.4% (CI 81.3–99.3%), and negative predictive
value of 99.3% (CI 98.3–99.8%). We did not observe any sta-
tistical difference of PCR sensitivity between amniocentesis
performed at the second or third trimester (p = 0.634). Only
one amniocentesis was performed in the ﬁrst trimester and it
was omitted from statistical analysis. Furthermore, we did not
ﬁnd a signiﬁcant difference (p = 0.315) of the time point of
maternal infection during pregnancy on the PCR result.
Data on timing of amniocentesis, serology, and treatment are
described in detail in Table 3. Our results demonstrated that a
higher number of amniocenteses were performed in the second
than in the third trimester (480 vs. 226). The time interval
between last negative and ﬁrst positive serology was signiﬁ-
cantly longer when amniocentesis was performed in the third
trimester (p <0.001). Time interval between seropositivity andTABLE 2. Amniotic ﬂuid polymerase chain reaction results in
women with serological conﬁrmed toxoplasma infection
during pregnancy (n [ 707)
Congenital Toxoplasmosis
TotalConﬁrmeda Ruled outa
AF PCR positive 34 (87.2%)
(CI 72.6–95.7%)
2 (0.3%) 36
AF PCR negative 5 (12.8%) 666 (99.7%)
(CI 98.9–100%)
671
Total 39 668 707
AF, amniotic ﬂuid; PCR, polymerase chain reaction; CI, conﬁdence interval.
aDiagnosis was conﬁrmed or ruled out by serological test, respectively, of infants
during the ﬁrst year of life.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Intime point of amniocentesis was also signiﬁcantly shorter in the
last trimester (p = 0.006). Consequently, duration of treatment
before amniocentesis was signiﬁcantly shorter in the third
trimester (p <0.001).
In our study cohort, 275/707 women (38.9%) received
amniocentesis before start of treatment (Table 3). The
remaining 432 were already treated before amniocentesis
(details on treatment are shown in Table 3). Treatment did not
signiﬁcantly inﬂuence sensitivity (p = 0.354) or speciﬁcity (p =
1.000) of the PCR.
After amniocentesis, 96.2% of all women with AI were
treated according to the Austrian regimen. We investigated
treatment of the remaining 3.8% (27/707): (a) Three of these
women did not receive any treatment, including two infected
miscarriages with positive PCR. (b) The remaining 24 women
received other medications, and 10 foetuses had CT (one
termination of pregnancy; ﬁve with positive, and four with false-
negative PCR results).
A detailed overview of serology, treatment, clinical mani-
festation and PCR in 39 infants with CT is shown in Table 1. In
28/39 infected infants (71.8%), no clinical manifestations were
reported at 1 year of age. In another two cases, prenatal ul-
trasound described mild cerebral ventriculomegaly and
hydronephrosis even though these abnormalities were not
observed after birth. Eight of 39 infected foetuses (20.5%)
already showed foetal abnormalities on prenatal ultrasound.
One infected infant with negative PCR was identiﬁed post-
natally, with retinochoroiditis and cerebral calciﬁcations at 2
months of age.DiscussionWe assessed the clinical use of amniocentesis for PCR in
pregnant women with Toxoplasma infection in a country with
mandatory screening. We observed that half of amniocentesesfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 191.e1–191.e8
TABLE 3. Timing of amniocentesis, maternal serology, and treatment of women with toxoplasma infection during pregnancy
Second trimester
amniocentesis
Third trimester
amniocentesis Total p
Number of amniocenteses, n (%) 480 (67.9%) 226 (32.0%) 707a NA
Median time point of amniocentesis (wk) 18 (16–21) 29 (28–32) 21 (17–28) NA
Median interval between seronegativity and seropositivity (weeks) 12.9 (9.6–16.0) 16.9 (13.1–19.3) 15.9 (11.0–18.3) <0.001b
Median interval between seropositivity and initiation of treatment (weeks) 0.3 (0.0–1.7) 0.6 (0.0–1.8) 0.3 (0.0–1.7) 0.470
Median interval between seropositivity and amniocentesis (weeks) 3.7 (1.0–6.0) 2.0 (0.9–4.7) 3.0 (0.9–5.9) 0.006b
Median time point of seronegativity (wk) 9 (7–11) 10 (8–14) 10 (8–13) NA
Median time point of seropositivity (wk) 14 (12–17) 27 (26–29) 16 (13–26) NA
Median time point of initiation maternal treatment (wk) 16 (13–18) 28 (27–30) 18 (14–26) NA
Median duration of maternal treatment (weeks) 24 (21–27) 11 (9–13) 21.4 (13–26) NA
Median duration of maternal treatment before amniocentesis (weeks) 2.0 (0.0–4.1) 0.7 (0.0–2.5) 1.6 (0.0–4.0) <0.001b
Treatment before amniocentesis: n (%) 309 (71.5%) 123 (28.5%) 432 NA
Spiramycin, n (%) 191 (91.4%) 18 (8.6%) 209 NA
Pyrimethamine/sulfadiazine + folinic acid, n (%) 60 (42.6%) 81 (57.4%) 141 NA
Spiramycin alternating with pyrimethamine/sulfadiazine + folinic acid, n (%) 58 (71.6%) 23 (28.4%) 81 NA
Other, n (%) 0 1 1 NA
No treatment before amniocentesis: n (%) 171 (62.2%) 103 (37.5%) 275a NA
Treatment after amniocentesis according the Austrian regimen 465 (68.4%) 214 (31.5%) 680a NA
Data are n (%) or median (95% CI). NA, not available; wk, weeks of gestational age.
aOne amniocentesis was performed at 12 weeks of gestational age.
bp Value <0.05 (uncorrected for multiple testing).
191.e6 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIwere performed without clinical justiﬁcation. Nonetheless,
most infants with CT could be identiﬁed accurately, but sero-
logical conﬁrmation is important at 1 year of age.
Amniocentesis is an important diagnostic tool to predict CT
prenatally [33], and may reduce parental stress due to imme-
diate clariﬁcation of foetal infection. This helps to reduce the
necessity of additional tests later in infants, like stressful and
painful lumbar puncture to conﬁrm CT [34]. In general,
amniocentesis is recommended for all women with AI to clarify
foetal infection, and should be part of prenatal counselling. The
register revealed that approximately 60% of women with AI
had amniocentesis. Most importantly, women with unclear/
indeterminate serology should not be punctured. Nonetheless,
a high proportion (49%) of amniocenteses were performed
without AI. One explanation is misinterpretation of serological
tests. In 8% (108/1386), serological retesting excluded AI, and
another 40% of women had chronic infection [28]. Conse-
quently, ﬁrst-line strategy in toxoplasmosis diagnostics is clari-
ﬁcation of maternal infection status using serological tests
before considering amniocentesis [28].
Furthermore, we observed a small number of women with
repeated amniocenteses (n = 7). These examinations did not
show any beneﬁt in providing additional diagnostic information.
Although experience in performing repeated amniocentesis is
limited, there is a lack of evidence for indication of serial
punctures. Nonetheless, in multiple pregnancies, infected and
non-infected foetuses were reported, and thus, we recommend
puncturing every single amniotic sac [35].
We, and others, have previously reported a high (87%) PCR
sensitivity [3–14,36]. In ﬁve infants with CT and negative PCR
results, the mothers were treated during pregnancy. These
infants were identiﬁed by positive IgM, missing IgG decrease, or
clinical manifestations. Consequently, there was a delay inClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectreccommendation of treatment. However, it is of utmost
importance to follow-up infants after birth, and to conﬁrm
infection by serology [37]. In cases of positive amniotic ﬂuid
PCR, it is essential to immediately start treatment to reduce
severe sequelae [38]. Only two cases with a false-positive PCR
were reported. These two mothers and their offspring were
treated but CT was ﬁnally excluded by serology at 1 year of age.
In contrast, in cases of negative PCR, no treatment was started
[32]. Consequently, we have a risk of CT in non-treated infants
with negative PCR result. Here, alternative strategies for
toxoplasmosis diagnostics, such as performing PCR from cord
blood or placenta at birth, were recently discussed [39,40]. In
many centres, the use of speciﬁc IgA, IgE, or Western blot
analyses is standard practice to identify infants at risk. These
diagnostic markers are valuable additional markers, although
the sensitivity for ﬁrst-line screening is low to exclude CT
[41–43].
Similar to previous studies, we could not ﬁnd any signiﬁcant
inﬂuence of treatment (p = 0.354), time point of maternal
infection during pregnancy (p = 0.315), or trimester of
amniocentesis (p = 0.634) on PCR [44]. Consequently, an
already-started treatment is not a contraindication for amnio-
centesis. Treatment should be started immediately in those
women with suspected maternal infection, and amniocentesis is
recommended after clariﬁcation. Additionally, amniocentesis is
also recommended in the last trimester reported with a higher
transmission risk [13], to clarify foetal infection to avoid un-
necessary treatment of the infant (up to 12 months) [32].
Consequently, we recommend amniocentesis even in late
maternal infections. Although the last infant was included in this
study in 2008, the current clinical routine shows that the sit-
uation has not changed, and the recommendations still hold at
present.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 191.e1–191.e8
CMI Prusa et al. Amniocentesis for the detection of congenital toxoplasmosis 191.e7The limitation of this study is that we could not differentiate
between false-negative PCR and transmissions that occurred
after amniocentesis in cases of CT with negative PCR. Another
limitation was the small number of cases of CT. Furthermore,
we included only identiﬁed maternal toxoplasma infections.
Not all seronegative women received a ﬁnal serology at birth,
thus infections could be unrecognized.
ConclusionAmniocentesis and PCR is a rapid and advantageous measure to
identify foetuses with CT. Our data demonstrated the practical
importance of a standardized clinical approach to use this
invasive procedure and to avoid unnecessary amniocentesis. In
cases of AI, PCR of amniotic ﬂuid has potential beneﬁts for
mother and child in appropriate therapeutical management and
outcome. Amniocentesis in chronically infected women is
without clinical justiﬁcation. We recommend amniocentesis
immediately after conﬁrmed serological diagnosis, even in the
situation of an already initiated treatment or late infection
during pregnancy. Serial amniocentesis did not demonstrate any
diagnostic beneﬁt. In multiple pregnancies, each amniotic sac
has to be punctured. A positive PCR result allows adequate
treatment in infants with CT to reduce severe sequelae.
Furthermore, we stress serological and clinical follow-up of
infants from mothers with AI for ﬁnal diagnosis, to identify all
infants at risk of CT in a timely manner.Transparency declarationThe authors declare that they have no conﬂicts of interest.References[1] Moncada PA, Montoya JG. Toxoplasmosis in the fetus and newborn: an
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